vigabatrin
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Complex Partial Seizures
Conditions
Complex Partial Seizures
Trial Timeline
Aug 1, 2010 → Dec 1, 2013
NCT ID
NCT01266291About vigabatrin
vigabatrin is a approved stage product being developed by Lundbeck for Complex Partial Seizures. The current trial status is terminated. This product is registered under clinical trial identifier NCT01266291. Target conditions include Complex Partial Seizures.
What happened to similar drugs?
6 of 18 similar drugs in Complex Partial Seizures were approved
Approved (6) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
20
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01413711 | Approved | Withdrawn |
| NCT01266291 | Approved | Terminated |
Competing Products
20 competing products in Complex Partial Seizures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zonisamide | Eisai | Phase 3 | 40 |
| Eslicarbazepine acetate + Eslicarbazepine acetate | Sumitomo Pharma | Phase 3 | 40 |
| Everolimus (RAD001) + Everolimus Placebo | Novartis | Phase 3 | 40 |
| Zoledronic acid + Placebo | Novartis | Phase 2 | 31 |
| RAD001 + Placebo | Novartis | Phase 2 | 35 |
| RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase) | Novartis | Phase 3 | 40 |
| everolimus | Novartis | Phase 3 | 44 |
| ranolazine | Gilead Sciences | Phase 2 | 35 |
| clarithromycin, rifabutin | Pfizer | Approved | 43 |
| Pregabalin + Pregabalin | Pfizer | Approved | 35 |
| Pregabalin | Pfizer | Pre-clinical | 18 |
| Azithromycin | Pfizer | Approved | 43 |
| Azithromycin + Rifabutin/rifampin | Pfizer | Approved | 43 |
| Stavudine | Bristol Myers Squibb | Phase 3 | 40 |
| Zidovudine + Didanosine | Bristol Myers Squibb | Phase 2 | 35 |
| Haemocomplettan® P + Human albumin (Placebo) | CSL | Phase 2/3 | 38 |
| BE1116 + FFP | CSL | Phase 3 | 47 |
| CSL730 + Placebo | CSL | Phase 1 | 21 |
| Sabril | Lundbeck | Approved | 40 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 29 |